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Abstract
Initial experience of transcatheter aortic valve implantation (TAVI) or replacement (TAVR) has ap-
peared as a promising minimally invasive technology for patients disqualified from surgical treatment 
(SAVR). Safety and efficacy of TAVI has been analyzed and assessed through numerous registries and 
trials. Furthermore, results obtained from comparative TAVI vs. SAVR trials proved that both treat-
ments can be considered equal in terms of post-procedural mortality and morbidity in high-risk, as well 
as lower risk patients. However, there are still some issues that have to be addressed, such as higher 
chance of paravalvular leakage, vascular injuries, conduction disturbances, malpositioning and the 
yet unmet problem of insufficient biological valves durability. Recent technological developments along 
with the learning curve of operators prove a great potential for improvement of TAVI and a chance of 
surpassing SAVR in various groups of patients in the near future. In pursuit of finding new solutions, 
the CardValve Consortium consisting of leading scientific and research institutions in Poland has been 
created. Under the name of InFlow and financial support from the National Center for Research and 
Development, they have started a project with the aim to design, create and implement into clinical 
practice the first, Polish, low-profile TAVI valve system, utilizing not only biological but also artificial, 
polymeric-based prosthesis. This review focuses on current developments in TAVI technologies including 
the InFlow project. (Cardiol J 2017; 24, 6: 685–694)
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Aortic stenosis:  
The scope of the problem
Valvular heart defects pose a serious chal-
lenge for healthcare systems in developed coun-
tries around the world, with aortic stenosis (AS) 
presenting the highest frequency of occurrence 
among them. Along with aging of societies, the 
prevalence of this disease rises drastically from 
0.7% in patients 18–44 years old to 13.3% in pa-
tients ≥ 75 years old [1].The European Society of 
Cardiology (ESC) in their recommendations for 
2012 estimates, that around 2–7% of people over 
65 years in Europe and the United States suffers 
from AS [2]. The main cause for its development 
remains valve calcification that increases with age. 
Calcium particles deposit in the valve, especially 
in the leaflets, leading to their thickening and 
hardening. As a result,  proper function of the valve 
is impaired. This mechanism differs from that oc-
curring in younger patients, in whom congenital 
defects are the most common cause of valve failure. 
Thanks to the development of medicine and rise of 
health awareness among men, rheumatic etiology, 
which was regarded as the main cause of valvular 
disease in the past, became a rare inducing factor. 
The disease itself can be divided into two phases: 
asymptomatic and symptomatic. Outcome predic-
tion in the asymptomatic phase is usually good 
and implementing medical treatment is sufficient. 
Duration of this period is long (several years), but 
varies among individuals. The onset of symptoms 
marks the beginning of the second, symptomatic 
phase, characterized by a rapid progression of 
illness.
The 5-year mortality, a parameter used to 
describe the severity of the disease is exception-
ally low for the symptomatic phase of AS, reach-
ing a survival rate of about 15–50% in groups of 
untreated patients [2]. This indicates a need for 
thorough diagnostics in risk group patients, con-
scientious monitoring and quick implementation 
of proper therapy. Searching for specific factors, 
which were identified as having a predictive value 
for turning AS into symptomatic phase is crucial. 
This includes: clinical factors such as older age or 
diffuse atherosclerosis, presence of calcification 
in components of aortic valve apparatus, low ejec-
tion fraction, hypertension, renal failure, positive 
results of exercise test meaning a high probability 
of symptoms onset within the next 12 months and 
elevated biomarkers (natriuretic peptide) [3].
Aortic valve replacement
Currently the gold standard in treatment of AS 
is surgical replacement of the valve (aortic valve 
replacement [AVR]), which comprises removal of 
a degenerated one and implantation of a biological 
or mechanical prosthesis in its place. In patients 
under 70 years, without serious comorbidities, 
perioperational mortality is 1–3%, however in older 
patients it rises to 4–8% [2]. Additional factors like 
concomitant diseases, female sex, patient fragility, 
higher New York Heart Association (NYHA) class 
or left ventricle dysfunction exacerbate the situa-
tion, drastically increasing the risk of death.
The development of medicine, improvement 
of civilizational life conditions and rise of social 
consciousness has resulted in increases of aver-
age lifespan. Mean age has risen, which directly 
translates into growth of perioperational risk and 
increasing difficulty in treatment of these patients. 
Studies show that 1/3 of patients over 75 years can-
not be qualified for surgical treatment [4]. This is 
mainly due to the very high risk of perioperative 
mortality. A need for new, less invasive treatment, 
customized for such patients has emerged.
Transcatheter aortic valve  
replacement — TAVI
In 1989, Henning-Rud Andersen first im-
planted an original model of a balloon-expandable 
catheter-mounted stented valve within the aorta of 
pigs, using a handmade mesh containing a porcine 
valve [5]. Over a decade later in 2002 the first suc-
cessful implantation of transcatheter aortic valve in 
clinical settings was performed by Alain Cribier in 
a patient suffering from severe AS caused by calci-
fication [6]. The method, under the name of TAVI 
(transcatheter aortic valve implantation) or TAVR 
(transcatheter aortic valve replacement), has been 
quickly implemented in clinical practice, marking 
the beginning of a new era of AS treatment. De-
pending on the option, biological prosthesis of the 
valve is implanted using dedicated catheter, with 
no need for surgery, via transapical (through the 
apex of the heart), or transvascular (mainly using 
femoral artery) route. Data from European Sentinel 
Registry of Transcatheter Aortic Valve Implanta-
tion indicate that femoral access is not only the 
preferred one, but also the safest (mortality of 
5.9% in comparison to 12.8% in transapical and 
9.7% in other access routes) [7]. Introducing this 
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technique happened to be a milestone and a chance 
for patients with critical health conditions who 
would have had unfavorable outcomes of surgery. 
Results of PARTNER 1B trial prove this statement. 
Performed comparison between TAVI and medical 
management in elderly patients deemed inoperable 
showed almost 22% difference in 5 year mortality 
(71.8% in the TAVI group vs. 93.6% in the standard 
treatment group; HR 0.50; 95% CI 0.39–0.65; p < 
< 0.0001) and 26% difference in number of patients 
presenting with satisfying results in heart failure 
management (NYHA class 1 and 2 symptoms) after 
5 years subsequent to the procedure (86% of TAVI 
group vs. 60% of the standard treatment group) [8]. 
Safety and efficacy of TAVI has been analyzed 
and assessed through numerous registries and tri-
als conducted. However, TAVI vs. surgical aortic 
valve replacement (SAVR) comparison has been 
evaluated in only 5 randomized trials, of which 
4 were completed. The STACCATO trial was ter-
minated early by the data safety monitoring board. 
The remaining (Table 1) include two high-risk trials 
(PARTNER 1A, US CoreValve High Risk) and three 
that covered non-high-risk patient populations 
(NOTION, PARTNER 2A, SURTAVI) [9, 10].
PARTNER 1A is the longest running trial 
with 5 year follow up, CoreValve was already in 
progress for 3 years and the other two for 2 years 
each. The most relevant outcomes for TAVI vs. 
SAVR are as follows. 
PARTNER 1A 5 years — no difference in mor-
tality (67.8% vs. 62.4%; p = 0.76), however TAVI 
patients more often suffered from major vascular 
complications (11.9% vs. 4.7%; p = 0.0002) and 
SAVR patients from major bleeding (26.6% vs. 
34.4%; p = 0.003) [11].
US CoreValve High Risk 3 years — no differ-
ence in mortality, but trending towards statistical 
significance in favor of TAVI (32.9% vs. 39.1%; 
p = 0.068). TAVI patients were more prone to the 
occurrence of major vascular complications and 
need for permanent pacemaker implant (7.1% vs. 
2.0%; p = 0.001; 28.0% vs. 14.5%; p < 0.001), 
whereas SAVR patients were prone to the risk of 
major bleeding and developing acute kidney injury 
(AKI) (32.8% vs. 40.0%; p = 0.045; 6.2% vs. 15.1%; 
p < 0.001) [12]. 
NOTION 4 years — no difference in mortal-
ity (20.0% vs. 23.0%; p = 0.56), greater need for 
permanent pacemaker implantation (PPI) in TAVI 
group (43.7% vs. 9.0%; p < 0.001), but SAVR pa-
tients were at higher risk of developing new atrial 
fibrillation (AF) or worsening the already existing 
condition (24.5% vs. 60.2%; p < 0.001) [13, 14].
PARTNER 2A 2 years — no difference in 
mortality (16.7% vs. 18.0%; p = 0.45), TAVI 
patients more often suffered from major vascular 
complications (8.6% vs. 5.5%; p = 0.006), although 
SAVR patients were more prone to experience 
life threatening bleeding complications and 
develop AKI or new AF (17.3% vs. 47.0%; 
p < 0.001; 3.8% vs. 6.2%; p = 0.02; 11.3% vs. 
27.3%; p < 0.001) [15]. 
SURTAVI 2 years — no difference in mortal-
ity (11.4% vs. 11.6%) and disabling stroke (2.6% 
vs. 4.5%) after 24 months, TAVI patients needed 
PPI more frequently (25.9% vs. 6.6%) and were at 
greater risk of presenting with vascular complica-
tions (6.0% vs. 1.1%), however SAVR patients more 
often suffered from AKI stage 2 or 3 (1.7% vs. 4.4%) 
and developed new AF (12.9% vs. 43.4%) [16].
The results obtained show that TAVI and 
SAVR are equivalent treatment methods in both 
high-risk and no-high-risk groups. Frequency of 
incidence of vascular complications and need for 
pacemaker implantation after TAVI can be par-
tially explained with the use of older generation 
valves in the above mentioned studies (Edwards 
SAPIEN, Medtronic CoreValve and SAPIEN XT) 
in comparison to the new ones available and many 
more under evaluation, which address these issues. 
Technological development along with the learn-
ing curve of operators proves a great potential for 
improvement of TAVI and a chance of surpassing 
SAVR in various groups of patients in the near fu-
ture. Optimistic clinical trial results and launching 
many new studies are reflected by the constantly 
growing number of TAVRs performed all over the 
world. A 33-fold increase has been recorded in 
the number of procedures performed annually in 
Europe between 2007 and 2011 [17].
TAVI limitations
Despite undisputed benefits, TAVI, as any 
other method, is not free from flaws. The most sig-
nificant flaws are the higher frequency of paraval-
vular leakage (PVL) in comparison to surgery and 
the large size of crimped valves requiring sheath 
of ≥ 14 F, resulting in the risk of vascular injuries 
during the delivery process. Also the need for 
pacemaker implantation due to relatively common 
occurrence of arrhythmias after the procedure and 
an inability to retrieve most of currently available 
valves in case of malposition remain important 
drawbacks. The conduction disorders are said to 
be connected with protrusion of the prosthesis 
into the left ventricular outflow tract (LVOT), 
www.cardiologyjournal.org 687
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mechanical injuries during predilatation or with the 
trauma caused by catheters and guidewires [18, 
19]. Inaccurate positioning is a rare but serious 
complication, which may end up with the need for 
second valve implantation and influences PVL due 
to impairing conformity of the prosthesis to native 
annulus. Worth mentioning here are incidences of 
cerebrovascular events due to ischemia. They can 
be explained with embolic debris being liberated 
from the native valve (especially heavy calcified) 
during the procedure, which then flows to cerebral 
circulation. Another possible explanation is brain 
hypoperfusion during valve implantation [20]. To 
reduce risk, few cerebral embolic protection de-
vices have been developed which either work as 
a collector or deflector of debris, namely the Claret 
CE Pro (Claret Medical Inc., Santa Rosa, CA), the 
Triguard (Keystone Heart, Caesarea, Israel), and 
the Embrella (Edwards Lifesciences Inc., Irvine, 
CA) [21].
Bulky delivery systems are the main cause of 
vascular injuries. Early reports stated that major 
vascular complications and bleeding occurred in 
8–17% of TAVI patients. Thankfully, due to tech-
nological advancement, better patient selection 
and gains in experience by medical staff, this has 
decreased to 4–13% of cases [22]. However, the 
need for a new low-profile device with a target of 
at least 12 F (3.96 mm) remains, as the number 
are still high. Developing and introducing a new 
product, will not only mean greater safety and util-
ity of TAVI, but may also positively affect patient 
comfort and owing to being less invasive, reduce 
recovery time. A different approach is creating 
and including expandable vascular sheaths which 
provide a temporary passage for prosthesis to 
prevent injuries. The examples are E-sheath and 
Solopath, which are also hydrophilic coated. To 
prevent bleeding associated with the puncture site, 
several closing devices have been developed to 
provide better sealing, including: Prostar (Abbott 
Vascular Inc, Santa Clara, CA), ProGlide (Abbott 
Vascular, Redwood City, CA), ProMed (ProMed, 
Santa Clara, CA), InSeal (InSeal Medical, Caesarea, 
Israel), VivaSure (VivaSure Medical Ltd., Galway, 
Ireland) [21]. 
Durability of TAVI prostheses remains in ques-
tion. Sufficient data exists only for a period of up 
to 5 years, showing promising results. However, 
much longer follow up is required for thorough 
analysis. Given the similarities to surgically im-
planted bioprostheses, the well known problem of 
structural valve deterioration can also be  an issue 
in TAVI, especially taking into account trending 
towards intermediate, younger patients [23]. Seek-
ing new methods of bio material preservation and 
alternatives in the form of biocompatible polymers 
should be of the essence.
Another essential case is the cost of implan-
tation and production of the valve, leading to the 
situation that even highly developed and wealthy 
countries such as Germany or Switzerland are 
being able to cover respectively only 36.2% and 
34.5% of their need with the European mean value 
holding at 17.9% [17]. It looks even worse in less 
wealthy countries like Poland, where healthcare 
funding is much lower, preventing its broader use 
and development.
Along with popularizing the method and imple-
menting new technologies the frequency of adverse 
events and costs of procedure should diminish. 
Constant education of physicians and other staff 
will have a positive effect on the safety and ease 
of implantation, translating into greater comfort 
for patients. Above mentioned issues pose a great 
challenge for researchers willing to improve the 
method.
New designs and solutions
In recent years new and interesting TAVI 
devices have been implemented into clinical prac-
tice with many more being currently under the 
evaluation process (Table 2) [24–28]. The coming 
years will show if they become breakthroughs in 
transcatheter treatment of aortic valves. Neverthe-
less, these technologies and solutions will have 
a chance to further improve the safety and efficacy 
of TAVI procedures. 
Boston Scientific has voluntarily recalled their 
Lotus valves in February 2017, including the Lotus 
with depth guard, following reports of problems 
with the device’s locking mechanism. The company 
expects that the issue will be resolved and device 
should return to European and other markets in 
the fourth quarter of 2017 [29].
Edwards SAPIEN 3 
New, commercially available balloon-expand-
able valve. Bovine pericardial tissue leaflets are 
mounted on a cobalt chromium alloy frame, which 
due to enhanced geometry design makes for 
a low-profile valve of 14 F enabling the reduction of 
vascular complications. SAPIEN 3 has an improved 
delivery system resulting in greater accuracy and 
lower risk of malpositioning. It also is comprised 
of an outer skirt of polyethylene terephthalate to 
minimize PVL [28].
www.cardiologyjournal.org 689
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Medtronic CoreValveEvolut-R
This self-expanding valve consists of a nitinol 
frame providing consistent radial force for better 
sealing. The valve is meant to be recapture- and 
reposition-able up to around 80% of deployment. 
The delivery system is 14 F equivalent to reduce 
the incidence of major vascular complications. The 
1-year data presented by Ganesh Manoharan at 
Trancatheter Cardiovascular Therapeutics (TCT) 
in 2015, showed a moderate PVL rate of 4.3% and 
PPI rate of 15.2%. The overall survivability rate 
was 93.3% [30].
Medtronic CoreValveEvolut PRO
Based on the same platform as Evolut-R, 
PRO is the new iteration of the CoreValve family. 
It contains an advanced sealing technology with 
porcine pericardial wrap on the lower part of the 
prosthesis, helping to reduce the number of inci-
dences of PVL. The valve is delivered with 14 F 
equivalent delivery system. 30-day result data 
presented at American College of Cardiology 
(ACC) 2017 showed good hemodynamics and 
the need for a pacemaker being as low as 10% 
[31]. Evolut PRO was approved by the Food 
and Drug Association (FDA) early this year and 
recently received Conformité Européenne (CE) 
mark [32]. 
Boston Scientific Lotus/Lotus Edge valve
The Lotus system consists of bovine pericardial 
tissue leaflets mounted on a nitinol frame. The valve 
is pre-attached to the delivery system. A mechanical 
expansion system enables full retrieval and repo-
sitioning of the valve unless it has been released. 
The operator can deploy the valve, leaving it in 
a lock position to evaluate positioning and perform 
necessary changes. Additionally, part of the frame 
is surrounded by Adaptive Seal™ to minimize PVL. 
The valve is currently available in CE mark coun-
tries and is under evaluation to obtain FDA approval 
[33, 34]. Lotus Edge is the next iteration of Lotus 
valve, characterized by a reduced profile of delivery 
catheter, which is also more flexible, enabling easier 
maneuvering and better control. Another important 
aspect is the introduction of a Depth Guard™ sys-
tem to minimize the protrusion of the valve into 
LVOT, thus diminishing the risk of post-procedural 
conduction disturbances and the need for PPI. First 
results from a feasibility trial presented at the TCT 
2016 seems promising. Lotus Edge is available in 
CE mark countries [35].
Table 2. Currently available and new transcatheter aortic valve implantation valves.
Valve Sheath size Special features Status
SAPIEN 3 14 F PET skirt, improved delivery system CE mark/FDA approved
CoreValveEvolut-R 14 F equivalent Repositionable up to 80% CE mark/FDA approved
CoreValveEvolut PRO 14 F equivalent Repositionable up to 80%, advanced 
sealing with porcine pericardial wrap
CE mark/FDA approved
Lotus/Lotus Edge* 18 F/14 F Fully retrievable, mechanical  
expansion system, adaptive Seal™, 
Depth Guard™ (Edge)
CE mark
JenaValve Pericardial 
TAVR System
Not available Clipping mechanism, repositionable 
before full deployment
Investigational use only
Portico 18 F Linx™ anti-calcification technology, 
minimal protrusion system,  
repositionable before full deployment
CE mark
Direct Flow Medical 18 F Inflatable ring cuff frame, fully  
retrievable
CE mark (production ceased)
Edwards CENTERA 14 F Motorized delivery system,  
repositionable before full deployment
Investigational use only
Acurate neo/TF 18 F Two-step, single-operator  
deployment process, three stabilization 
arches, covered with porcine  
pericardial skin
CE mark only
Engager 32 F (transapical) Polyester skirt, control arms CE mark only (recalled) 
*Boston Scientific has voluntarily recalled their Lotus valves in February 2017, including the Lotus with depth guard, following reports of 
problems with the device’s locking mechanism. The company expects that the issue will be resolved and device should return to European 
and other markets in the fourth quarter of 2017 [29]. CE — Conformité Européenne; FDA — Food and Drug Association; PET — polyethylene 
terephthalate
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JenaValve Pericardial TAVR System
The self-expanding, nitinol frame system is 
based on a company’s previous CE marked Jena-
Valve porcine root system. It is designed to address 
both the stenosis and regurgitation issue. The 
valve uses a unique clipping mechanism, enabling 
fixation to native leaflets for greater stability. The 
efficiency of this mechanism is said to be independ-
ent of the level of calcification of a native valve. 
Producer declares that the valve is to be reposition-
able even after locator release, but prior to stent 
deployment, lowering the risk of malpositioning. 
Currently, the system is enabled exclusively for 
investigational use [36]. 
St. Jude Medical Portico valve
Portico is a bovine leaflets valve, processed 
with Linx™ anti-calcification technology, based on 
nitinol stent frame with a cuff, also made of bovine 
pericardial tissue, working as a sealing zone to 
minimize PVL [37]. The valve is gradually deployed 
using 18 F delivery system, allowing recapturing 
and repositioning of the valve until the complete 
deployment. The height of the valve is designed 
to result in minimal protrusion into the LVOT, re-
ducing the incidence of post-procedural pacemaker 
implantation. Currently Portico bears a CE mark, 
available in Europe and is continuing its IDE trial 
in the United States [38].
Direct flow valve
The Direct Flow Medical aortic valve (Direct 
Flow Medical, Santa Rosa, CA, USA) is a non-
metallic percutaneous valve with an inflatable ring 
cuff frame designed to encircle and capture the 
native valve annulus, thereby ensuring anchor-
ing of the bioprosthesis and minimizing potential 
paravalvular aortic regurgitation, dislodgment or 
migration [39]. The valve is designed to conform 
to individual anatomy for a better seal and is meant 
to be fully retrievable and repositionable prior to 
deployment. The inflatable rings are pressurized 
with saline and contrast solution resulting in great 
visibility of the prosthesis, translating into easier 
and more accurate positioning with no need for 
contrast injections during deployment. After evalu-
ation the solution is then exchanged for a polymer, 
which solidifies making for a permanent support 
structure [40]. The system has received CE mark, 
however it is not available presently. The company 
closed and had ceased production at the end of No-
vember 2016 after failing to secure financing [41]. 
Other valves
Other valves worth mentioning are: Edwards 
CENTERA valve, characterized with low profile 
of 14 F and is self-expanding, retrievable and 
repositionable until full deployment. The use of 
a motorized delivery system allows for single 
operator use [22]. So far the valve is enabled for 
investigational use only. Thirty-day outcomes 
presented at EuroPCR 2017 showed excellent 
results in terms of mortality (1%) and need for 
pacemaker implantation (4.9%) [42]. Symetis Acu-
rate neo/TF system facilitates an easy two-step, 
single-operator deployment process. The device 
is comprised of three stabilization arches for axial 
alignment, an upper-crown for capping the aortic 
annulus, and a lower-crown that is opened over 
the native valve for full deployment. Additionally, 
the stent is covered with porcine pericardial skin 
to minimize leakage. The system has received CE 
mark and is available on the European market [43, 
44]. Medtronic Engager is a self-expanding valve 
with nitinol stent frame covered with polyester 
skirt. The system presents with control arms 
for tactile feedback during deployment, enabling 
more precise positioning and greater conformity 
to the native annulus, resulting in a reduction of 
PVL [45, 46]. The Medtronic Engager system is 
CE mark approved. Despite positive early results, 
Medtronic decided to voluntarily recall all devices 
in 2015 after reviewing 2-year data from Engager 
European Pivotal trial showing suboptimal results 
of mean gradient [47]. 
InFlow project
Bearing in mind the above mentioned TAVI 
limitations, as well as specificity of the Polish 
medical market, CardValve Consortium has been 
brought to life and commenced work on an InFlow 
project. Its purpose is to create the first Polish, 
low profile valve for transcatheter implantation. 
Through funds received from the National Cen-
tre for Research and Development as a part of 
STRATEGMED program, this vision has become 
possible to accomplish.
The aim of the Consortium is to introduce to 
the market a valve, which owing to the low profile, 
will enable minimization of vascular injuries con-
nected with the delivery process and due to being 
composed of new materials will be characterized 
by higher biocompatibility and durability of single 
elements which are safer for patients. The desired 
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size of the whole system is 12 F or less, which 
would be a huge step forward. The newest, state 
of the art valves like Medtronic Evolut-R™ or 
Edwards SAPIEN 3 have a sheath size of 14 F and are 
the smallest among competitors. Others normally 
start from 18 F. Implementing a native product in 
clinical practice will also reduce costs of procedures 
using TAVI valves, considering its lower price in 
comparison to currently available products. It is 
hoped to result in greater accessibility for patients.
Project timeline
Project began on 1st of October 2014 and is 
planned to conclude in the second half of 2017. The 
protocol assumes selection of the most optimal valve 
design and materials for prototype production, and 
subsequently implementation of preclinical studies 
in order to introduce this device into clinical tests. 
The aim of the project is not only creating a new valve 
itself, but also a complete implantation device consist-
ing of a delivery system made of dedicated inflating 
balloon, self-positioning frame and vascular sheath.
Obtaining proper material for leaflet produc-
tion is essential. For this purpose, various polymer 
combinations are being tested under laboratory 
conditions to assess their mechanical properties 
and hemocompatibility as well as their biocompat-
ibility on animal models. Simultaneously, research 
on finding biological material is being carried out, 
focused on swine pericardium selected from ani-
mals which have an individual diet [48, 49].
Designing and creating a thin, self-positioning 
frame for the valve, presenting with high radial 
force and complete low-profile delivery system 
is another crucial step. Stent, constituting a scaf-
fold will be laser cut from respective and properly 
treated cobalt-chromium alloy to enhance its du-
rability and biocompatibility.
Positive completion of this phase and creation 
of functional prototype of TAVI system enables 
transition to the second stage of the project, 
covering the evaluation of feasibility, ease of im-
plantation and safety in long-term observation on 
a large animal model. Findings of this phase will 
translate into diminishing the hazard for patients 
during enrollment for clinical trial and its results 
will be more unambiguous.
Current state of the project  
(as of the mid 2017)
To date, the project has already been in pro-
gress for more than 2.5 years. During this time 
important milestones have been accomplished. 
First of all, the scaffold of the valve was designed 
and created, as well as a prototype delivery sys-
tem. Secondly, from among dozens of various 
polymers, the most optimal one was chosen and 
tested within the animal model within the aspect 
of biocompatibility. Recently, artificial and biologi-
cal valve prototypes were constructed and tested 
with the use of flow pump [50]. The tests showed 
proper function of the opening/closing mechanism 
with preserved large area of opening. Concurrently, 
the InFlow-dedicated TAVI balloon was tested in 
in-vivo settings. Functionality was confirmed, with 
a new balloon pattern enabling precise position-
ing of implanted valve and reducing frequency of 
vascular complications connected with in-vessel 
maneuvering of the delivery system. The first 
implantations of both biological and polymeric 
valve prototypes with a dedicated delivery system 
have been performed during the first half of August 
2017. Ovine was chosen as the most adequate 
animal model.
Conclusions
Cribier’s first performed TAVI procedure 
marked the beginning of a revolution of severe AS 
treatment. Clinical trials and registries confirmed 
the efficacy and safety of the new method, simul-
taneously outlining the most frequent and severe 
complications, pointing out possible flaws and inad-
equacies. New designs and technologies, address-
ing the most critical issues, as well as continuous 
education and gathering of experience by physi-
cians will hopefully contribute to reducing adverse 
event frequency and severity in the near future. 
Additionally, improving the method will translate 
into a possibility to implement it into lower risk 
groups and extending its range. Undertaking the 
challenge of developing new product by CardValve 
Consortium is a good sign that TAVI development 
market is not limited to a few main players. What 
is more, proposed solutions will result in creat-
ing a technologically advanced device, positively 
influencing patient comfort, safety and diminish-
ing costs of the procedure, making it more within 
reach for patients. If the created product confirms 
its efficacy and ease of use, it can be successfully 
used as a basis for developing and implementing 
consecutive new technologies in the cardiovascular 
field. TAVI holds a great potential for improvement 
and becoming the gold standard in AS treatment, 
surpassing the classic methods. Only time will tell 
whether it meets expectations.
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